Q-omics provides the consensus-scored LARP1B profile across patient tissues and cancer cell-line models. LARP1B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LARP1B is differentially expressed in 10, with the highest sampling consensus in STAD. Additionally, LARP1B RNA expression shows 20,546 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, STAD, and UVM as cancer lineages where LARP1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LARP1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LARP1B survival associations across molecular data types. LARP1B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LARP1B RNA expression–survival associations across cancer types. High LARP1B expression shows unfavorable associations in LGG and UVM, but favorable associations in KIRC, READ, SKCM and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LARP1B RNA expression.
This table summarizes LARP1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in STAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LARP1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LARP1B shows lower tumor expression in THCA and higher tumor expression in STAD, LUAD, BRCA, KIRC and UCEC. The STAD box plot shows higher LARP1B RNA expression in tumor versus normal tissue (log2 FC = +0.465, t-test p < 0.001).
This table shows molecular features associated with LARP1B in patient tissues and cancer cell lines. In patient samples, LARP1B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LARP1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and CNS.
